AB Science's masitinib meets in ALS study

AB Science S.A. (Euronext:AB) gained €2.04 (13%) to €17.36 after it said the higher of two doses of masitinib (AB1010) met the primary endpoint in the Phase II/III AB10015 study to treat amyotrophic lateral sclerosis. A 4.5 mg/kg/day dose of masitinib significantly improved revised ALS Functional Rating Scale (ALSFRS-R) score from baseline to week 48 vs. placebo (p=0.014).

The dose also met the secondary endpoints of improving progression-free survival (PFS) (p=0.016) and quality of life as measured by the ALS Assessment Questionnaire (ALSAQ) vs. placebo (p<0.01)...